AZD2014 (Vistusertib)

Status: Currently a NF2 Clinical Trial

Trade Name	Vistusertib
Other Names	AZD2014, AZD-2014, AZD 2014
Pharmaceutical Companies	AstraZeneca
NF2 Trial Availability	USA 2017
Taken By	Pill (oral)
Tumor Target	Recurrent Meningioma
NF2 Trials	https://clinicaltrials.gov/ct2/show/NCT03071874 Recruiting Trial: NCT02831257 | Neurofibromatosis 2 (NF2) - Meningioma | Phase 2: July 2016 Not Open: NCT03071874 | Multiple Meningioma | Phase 2: April 15, 2017
Inhibitor	mammalian Target of Rapamycin (mTOR); Autophagy; mTORC1/mTORC2
Molecular Formula	C25H30N6O3

Early trial results in individuals with neurofibromatosis type 2 (NF2 / MERLIN), so far indicate the treatment may help shrink Meningioma by up to eighteen percent (18%).

Also in Trials for:

• Conditions
• Stomach Neoplasms
• Advanced Cancer
• Solid Tumor
• Prostate Cancer
• Advanced Metastatic Breast Cancer
• Glioblastoma Multiforme
• Core: Relapsed or Refractory Diffuse Large B-Cell Lymphoma|Module 1: Non-GCB Diffuse Large B-Cell Lymphoma
• Advanced Solid Malignancies
• Metastatic Clear Cell Renal Carcinoma
• Meningioma
• Breast Cancer|Malignant Female
• Reproductive System Neoplasm
• Neurofibromatosis 2|Meningioma
• Triple-Negative Breast Cancer|Squamous Cell Lung Cancer|Non-squamous Cell Lung Cancer With KRAS Mutations|Non-squamous Cell Lung Cancer With Wild-type KRAS

Sources

1. Apra, Caroline, Matthieu Peyre, and Michel Kalamarides. "Current treatment options for meningioma." Expert review of neurotherapeutics 18.3 (2018): 241-249. DOI: https://doi.org/10.1080/14737175.2018.1429920 | Source: https://www.tandfonline.com/doi/abs/10.1080/14737175.2018.1429920
2. Pike Kurt G., Malagu Karine, Hummersone Marc G., Menear Keith A., Duggan Heather M.E., Gomez Sylvie, Martin Niall M.B., Ruston Linette, Pass Sarah L., "Pass Martin. Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014." Bioorganic & Medicinal Chemistry Letters, (2013)
   Source: https://www.sciencedirect.com/science/article/pii/S0960894X13000413?via%3Dihub | DOI: 10.1016/j.bmcl.2013.01.019
3. Ma Xiao-Dong, Qiu Ni, Yang Bo, He Qiao-Jun, Hu Yong-Zhou. "Novel quinoline-derived mTOR inhibitors with remarkable enzymatic and cellular activities: design, synthesis and biological evaluation." Med. Chem. Commun., (2016)
   Source: http://pubs.rsc.org/en/Content/ArticleLanding/2016/MD/C5MD00401B#!divAbstract | DOI: 10.1039/C5MD00401B
4. "AZD2014" National Center for Biotechnology Information. PubChem Compound Database; CID=25262792, https://pubchem.ncbi.nlm.nih.gov/compound/25262792
5. Mawrin, Christian. "Looking for the needle in the haystack: Proteome-based identification of treatment targets in NF2-related nervous system tumors." EBioMedicine 16 (2017): 6-7.
   Source: http://www.sciencedirect.com/science/article/pii/S2352396417300488| DOI: 10.1016/j.ebiom.2017.01.044